Clinical trial NCT01774032: H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older
Official title: An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Influenza
Lead sponsor: Resilience Government Services, Inc.
Sponsor class: INDUSTRY
First posted: 2013-01-23
Enrollment: 91
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.


Eligibility criteria: Inclusion Criteria:

* Participant is 65 years or older at the time of screening.
* Participant is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination.
* Participant is physically and mentally capable of participating in the study.
* Participant is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

* Participant has a history of infection with H5N1 virus or a history of vaccination with an H5N1 influenza vaccine.
* Participant is at high risk of contracting H5N1 influenza infection (e.g., poultry workers).
* Participant currently has or has a history of a significant cardiovascular (including hypertension), respiratory (including asthma), metabolic, neurological (including Guillain-Barré Syndrome and acute disseminated encephalomyelitis), hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder.
* Participant has any inherited or acquired immunodeficiency.
* Participant has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to: systemic or inhaled corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs.
* Participant has a history of severe allergic reactions or anaphylaxis.
* Participant has a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating.
* Participant has received a blood transfusion or immunoglobulins within 90 days prior to study entry.
* Participant has donated blood or plasma within 30 days prior to study entry.
* Participant has received any influenza or any live vaccine within 4 weeks or any other inactivated vaccine within 2 weeks prior to vaccination in this study.
* Participant has a functional or surgical asplenia.
* Participant has a known or suspected problem with alcohol or drug abuse.
* Participant has been exposed to an investigational product (IP) within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
* Participant is a family member or employee of the investigator.
* Participant has any other condition that disqualifies his/her participation in the study in the opinion of the investigator.

Primary outcomes:
measure: Co-Primary Evaluation of Immunogenicity by Single Radial Hemolysis (SRH) Assay: Number of participants with antibody response to vaccine strain (A/Indonesia/05/2005)
timeFrame: Day 43 (42 days after first vaccination, 21 days after second vaccination)
measure: Co-Primary Evaluation of Immunogenicity by SRH Assay: Number of participants demonstrating seroconversion 21 days after the second vaccination
timeFrame: Day 43 (42 days after first vaccination, 21 days after second vaccination)
measure: Co-Primary Evaluation of Immunogenicity by SRH Assay: Fold increase of antibody response 21 days after the second vaccination as compared to baseline
timeFrame: Day 43 (42 days after first vaccination, 21 days after second vaccination)
Secondary outcomes:
measure: Evaluation of Immunogenicity by SRH Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)
timeFrame: Days 22 and 202
measure: Evaluation of Immunogenicity by SRH Assay: Number of participants demonstrating seroconversion 21 days after the first and 180 days after the second vaccination
timeFrame: Days 22 and 202
measure: Evaluation of Immunogenicity by SRH Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by SRH Assay: Fold increase of antibody response 21 days after the first and 180 days after the second vaccination as compared to baseline
timeFrame: Days 22 and 202
measure: Evaluation of Immunogenicity by Microneutralization (MN) Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by MN Assay: Number of participants demonstrating seroconversion 21 days after the first and 21 and 180 days after the second vaccination
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by MN Assay: Number of participants demonstrating either ≥4-fold titer increase compared to baseline if above detection limit OR ≥ 20 titer after vaccination if baseline titer is below detection limit
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by MN Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by MN Assay: Fold increase of antibody response 21 days after the first and 21 and 180 days after the second vaccination as compared to baseline
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by Hemagglutination Inhibition (HI) Assay: Number of participants with antibody response to the vaccine strain (A/Indonesia/05/2005)
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by HI Assay: Number of participants demonstrating seroconversion 21 days after the first and 21 and 180 days after the second vaccination
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by HI Assay: Antibody response 21 days after the first and 21 and 180 days after the second vaccination
timeFrame: Days 22, 43 and 202
measure: Evaluation of Immunogenicity by HI Assay: Fold increase of antibody response 21 days after the first and 21 and 180 days after the second vaccination as compared to baseline
timeFrame: Days 22, 43 and 202
measure: Frequency and severity of injection site and systemic reactions until 21 days after the first and second vaccinations
timeFrame: Through study day 43
measure: Number of participants with fever, malaise or shivering with onset within 7 days after the first and second vaccinations
timeFrame: Days 1-8 and days 22-29
measure: Frequency and severity of all adverse events (AEs) observed during the entire study period
timeFrame: Throughout the study period- 8 months
Other outcomes:
Locations:
city: Fukuoka City
country: Japan
facility: PS Clinic
city: Osaka City
country: Japan
facility: Osaka Pharmacology Clinical Research Hospital (OPHAC Hospital)
Study officials:
affiliation: Baxter Innovations GmbH
name: Nirjhar Chatterjee, MD
role: STUDY_DIRECTOR
References: